Details of the Drug

General Information of Drug (ID: DMQUSBT)

Drug Name
Daunorubicin
Synonyms
daunorubicin; Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Acetyladriamycin; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline
Indication
Disease Entry ICD 11 Status REF
Acute monocytic leukemia N.A. Approved [1]
Acute myelogenous leukaemia 2A41 Approved [1]
Acute myeloid leukaemia 2A60 Approved [2]
Kaposi sarcoma 2B57 Approved [3]
Leukemia N.A. Approved [1]
Solid tumour/cancer 2A00-2F9Z Phase 2 [4]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 527.5
Logarithm of the Partition Coefficient (xlogp) 1.8
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 5
Hydrogen Bond Acceptor Count (hbondacc) 11
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 24.8 mg/L [5]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 2 h [5]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [6]
Clearance
The drug present in the plasma can be removed from the body at the rate of 47.57 mL/min/kg [7]
Elimination
40% of daunorubicin is excreted in the bile while 25% is excreted in an active form (daunorubicin or daunorubicinol) in the urine [8]
Half-life
The concentration or amount of drug in body reduced by one-half in 18.5 +/- 4.9 hours [9]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 2.04727 micromolar/kg/day [10]
Unbound Fraction
The unbound fraction of drug in plasma is 0.06% [7]
Vd
The volume of distribution (Vd) of drug is 6.6 L [9]
Water Solubility
The ability of drug to dissolve in water is measured as 0.0392 mg/mL [6]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Bone marrow failure rs6603859 SEC14L3 OTGQ8GWM [11]
Cardiotoxicity rs7853758 SLC28A3 OT5TLTYU [12]
Cardiotoxicity rs17863783 UGT1A6 OTGTQ2C9 [12]
Chemical Identifiers
Formula
C27H29NO10
IUPAC Name
(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
Canonical SMILES
C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O
InChI
InChI=1S/C27H29NO10/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3/t10-,14-,16-,17-,22+,27-/m0/s1
InChIKey
STQGQHZAVUOBTE-VGBVRHCVSA-N
Cross-matching ID
PubChem CID
30323
ChEBI ID
CHEBI:41977
CAS Number
20830-81-3
DrugBank ID
DB00694
TTD ID
D01XWG
VARIDT ID
DR00284
INTEDE ID
DR0424
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA replication (DNA repli) TTABD5E NOUNIPROTAC Modulator [13]
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Intercalator [14]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 6 (ABCC6) DT582KR MRP6_HUMAN Substrate [15]
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [16]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [17]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [18]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [19]
Cytochrome P450 1A1 (CYP1A1) DE6OQ3W CP1A1_HUMAN Substrate [19]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [19]
NADPH-cytochrome P450 reductase (CPR) DE3N2FM NCPR_HUMAN Substrate [20]
NADPH-dependent carbonyl reductase 1 (CBR1) DE9JFMC CBR1_HUMAN Substrate [21]
NADPH-dependent carbonyl reductase 3 (CBR3) DEIVKZ8 CBR3_HUMAN Substrate [22]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Actin, alpha skeletal muscle (ACTA1) OTOVGLPG ACTS_HUMAN Gene/Protein Processing [23]
Agrin (AGRN) OTWJENAZ AGRIN_HUMAN Gene/Protein Processing [24]
Aldo-keto reductase family 1 member A1 (AKR1A1) OTZT9NOW AK1A1_HUMAN Biotransformations [25]
Aldo-keto reductase family 1 member B1 (AKR1B1) OTRX72TH ALDR_HUMAN Biotransformations [26]
Aldo-keto reductase family 1 member B10 (AKR1B10) OTOA4HTH AK1BA_HUMAN Drug Response [27]
Aldo-keto reductase family 1 member C3 (AKR1C3) OTU2SXBA AK1C3_HUMAN Drug Response [28]
Androgen receptor (AR) OTUBKAZZ ANDR_HUMAN Gene/Protein Processing [29]
Ankyrin-2 (ANK2) OTWB4R1Y ANK2_HUMAN Gene/Protein Processing [23]
Annexin A2 (ANXA2) OTFNS0CC ANXA2_HUMAN Gene/Protein Processing [30]
Annexin A4 (ANXA4) OTUCRYXL ANXA4_HUMAN Gene/Protein Processing [24]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Daunorubicin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Daunorubicin and Ivosidenib. Acute myeloid leukaemia [2A60] [31]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Midostaurin. Acute myeloid leukaemia [2A60] [32]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Idarubicin. Acute myeloid leukaemia [2A60] [32]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Arn-509. Acute myeloid leukaemia [2A60] [33]
Gilteritinib DMTI0ZO Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Gilteritinib. Acute myeloid leukaemia [2A60] [34]
Coadministration of a Drug Treating the Disease Different from Daunorubicin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sarecycline DMLZNIQ Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Sarecycline . Acne vulgaris [ED80] [35]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Oliceridine. Acute pain [MG31] [32]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Daunorubicin and Rivastigmine. Alzheimer disease [8A20] [32]
Donepezil DMIYG7Z Moderate Increased risk of ventricular arrhythmias by the combination of Daunorubicin and Donepezil. Alzheimer disease [8A20] [32]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Daunorubicin and Metronidazole. Amoebiasis [1A36] [36]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Daunorubicin and Ivabradine. Angina pectoris [BA40] [33]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Daunorubicin and Bepridil. Angina pectoris [BA40] [32]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Daunorubicin and Dronedarone. Angina pectoris [BA40] [32]
Nifedipine DMSVOZT Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Nifedipine. Angina pectoris [BA40] [35]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Daunorubicin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [37]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Cilostazol. Arterial occlusive disease [BD40] [32]
Posaconazole DMUL5EW Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Posaconazole. Aspergillosis [1F20] [35]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Daunorubicin and Levalbuterol. Asthma [CA23] [38]
Terbutaline DMD4381 Moderate Increased risk of ventricular arrhythmias by the combination of Daunorubicin and Terbutaline. Asthma [CA23] [39]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Daunorubicin and Pirbuterol. Asthma [CA23] [39]
Salbutamol DMN9CWF Moderate Increased risk of ventricular arrhythmias by the combination of Daunorubicin and Salbutamol. Asthma [CA23] [38]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Daunorubicin and Roflumilast. Asthma [CA23] [33]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Daunorubicin and Formoterol. Asthma [CA23] [39]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [33]
Desipramine DMT2FDC Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Desipramine. Attention deficit hyperactivity disorder [6A05] [32]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Ofloxacin. Bacterial infection [1A00-1C4Z] [40]
Clarithromycin DM4M1SG Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Clarithromycin. Bacterial infection [1A00-1C4Z] [35]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Daunorubicin and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [32]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Daunorubicin and Sparfloxacin. Bacterial infection [1A00-1C4Z] [40]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Gemifloxacin. Bacterial infection [1A00-1C4Z] [40]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Norfloxacin. Bacterial infection [1A00-1C4Z] [40]
ABT-492 DMJFD2I Minor Decreased absorption of Daunorubicin due to intestinal mucosa variation caused by ABT-492. Bacterial infection [1A00-1C4Z] [41]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Levofloxacin. Bacterial infection [1A00-1C4Z] [40]
Lomefloxacin DMVRH9C Minor Decreased absorption of Daunorubicin due to intestinal mucosa variation caused by Lomefloxacin. Bacterial infection [1A00-1C4Z] [41]
Telithromycin DMZ4P3A Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Telithromycin. Bacterial infection [1A00-1C4Z] [35]
Ag-221 DMS0ZBI Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Ag-221. BCR-ABL1-negative chronic myeloid leukaemia [2A41] [36]
Retigabine DMGNYIH Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Retigabine. Behcet disease [4A62] [35]
Erdafitinib DMI782S Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [42]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Loperamide. Bowel habit change [ME05] [43]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Eribulin. Breast cancer [2C60-2C6Y] [32]
Lapatinib DM3BH1Y Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Lapatinib. Breast cancer [2C60-2C6Y] [35]
HKI-272 DM6QOVN Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by HKI-272. Breast cancer [2C60-2C6Y] [35]
Tucatinib DMBESUA Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Tucatinib. Breast cancer [2C60-2C6Y] [35]
Alpelisib DMEXMYK Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Alpelisib. Breast cancer [2C60-2C6Y] [35]
Atorvastatin DMF28YC Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Atorvastatin. Cardiovascular disease [BA00-BE2Z] [35]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [44]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Olodaterol. Chronic obstructive pulmonary disease [CA22] [39]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Vilanterol. Chronic obstructive pulmonary disease [CA22] [38]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Daunorubicin and Salmeterol. Chronic obstructive pulmonary disease [CA22] [39]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Daunorubicin and Indacaterol. Chronic obstructive pulmonary disease [CA22] [39]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Daunorubicin and Arformoterol. Chronic obstructive pulmonary disease [CA22] [39]
Isoproterenol DMK7MEY Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Isoproterenol. Conduction disorder [BC63] [38]
Ulipristal DMBNI20 Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Ulipristal. Contraceptive management [QA21] [35]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Halothane. Corneal disease [9A76-9A78] [32]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Propofol. Corneal disease [9A76-9A78] [45]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Sevoflurane. Corneal disease [9A76-9A78] [32]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Probucol. Coronary atherosclerosis [BA80] [32]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Clofazimine. Crohn disease [DD70] [46]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Daunorubicin and Mifepristone. Cushing syndrome [5A70] [32]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Daunorubicin and Pasireotide. Cushing syndrome [5A70] [32]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Osilodrostat. Cushing syndrome [5A70] [33]
Ivacaftor DMZC1HS Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Ivacaftor. Cystic fibrosis [CA25] [35]
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Sertraline. Depression [6A70-6A7Z] [32]
Trimipramine DM1SC8M Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Trimipramine. Depression [6A70-6A7Z] [32]
Nefazodone DM4ZS8M Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Nefazodone. Depression [6A70-6A7Z] [35]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Daunorubicin and Escitalopram. Depression [6A70-6A7Z] [32]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Clomipramine. Depression [6A70-6A7Z] [32]
Doxepin DMPI98T Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Doxepin. Depression [6A70-6A7Z] [32]
Maprotiline DMPWB7T Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Maprotiline. Depression [6A70-6A7Z] [32]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [32]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Deutetrabenazine. Dystonic disorder [8A02] [47]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Ingrezza. Dystonic disorder [8A02] [48]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Solifenacin. Functional bladder disorder [GC50] [32]
Itraconazole DMCR1MV Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Itraconazole. Fungal infection [1F29-1F2F] [35]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Pentamidine. Fungal infection [1F29-1F2F] [32]
Ketoconazole DMPZI3Q Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Ketoconazole. Fungal infection [1F29-1F2F] [35]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Sunitinib. Gastrointestinal stromal tumour [2B5B] [32]
Boceprevir DMBSHMF Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Boceprevir. Hepatitis virus infection [1E50-1E51] [35]
Telaprevir DMMRV29 Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Telaprevir. Hepatitis virus infection [1E50-1E51] [35]
Daclatasvir DMSFK9V Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Daclatasvir. Hepatitis virus infection [1E50-1E51] [35]
Delavirdine DM3NF5G Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Delavirdine. Human immunodeficiency virus disease [1C60-1C62] [35]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [49]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Daunorubicin and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [50]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [32]
Teriflunomide DMQ2FKJ Major Additive myelosuppressive effects by the combination of Daunorubicin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [51]
BMS-201038 DMQTAGO Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by BMS-201038. Hyper-lipoproteinaemia [5C80] [35]
Felodipine DMOSW35 Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Felodipine. Hypertension [BA00-BA04] [35]
Conivaptan DM1V329 Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Conivaptan. Hypo-osmolality/hyponatraemia [5C72] [35]
Tolvaptan DMIWFRL Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [35]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Daunorubicin and Polyethylene glycol. Irritable bowel syndrome [DD91] [33]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Daunorubicin and Denosumab. Low bone mass disorder [FB83] [52]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Daunorubicin and Crizotinib. Lung cancer [2C25] [53]
Brigatinib DM7W94S Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Brigatinib. Lung cancer [2C25] [35]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Daunorubicin and Ceritinib. Lung cancer [2C25] [32]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Daunorubicin and Osimertinib. Lung cancer [2C25] [54]
Capmatinib DMYCXKL Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [35]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Daunorubicin and Selpercatinib. Lung cancer [2C25] [33]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Daunorubicin and Lumefantrine. Malaria [1F40-1F45] [36]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Daunorubicin and Halofantrine. Malaria [1F40-1F45] [55]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Daunorubicin and Hydroxychloroquine. Malaria [1F40-1F45] [56]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Primaquine. Malaria [1F40-1F45] [32]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Daunorubicin and Arsenic trioxide. Mature B-cell lymphoma [2A85] [57]
Ponatinib DMYGJQO Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Ponatinib. Mature B-cell lymphoma [2A85] [35]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Daunorubicin and Vemurafenib. Melanoma [2C30] [32]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and LGX818. Melanoma [2C30] [58]
Lasmiditan DMXLVDT Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Lasmiditan. Migraine [8A80] [59]
Flibanserin DM70DTN Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Flibanserin. Mood disorder [6A60-6E23] [35]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Daunorubicin and Panobinostat. Multiple myeloma [2A83] [60]
Thalidomide DM70BU5 Major Additive thrombogenic effects by the combination of Daunorubicin and Thalidomide. Multiple myeloma [2A83] [61]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Daunorubicin and Tecfidera. Multiple sclerosis [8A40] [62]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Daunorubicin and Siponimod. Multiple sclerosis [8A40] [36]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Daunorubicin and Fingolimod. Multiple sclerosis [8A40] [63]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Daunorubicin and Ocrelizumab. Multiple sclerosis [8A40] [64]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Daunorubicin and Ozanimod. Multiple sclerosis [8A40] [33]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Romidepsin. Mycosis fungoides [2B01] [32]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Daunorubicin and Nilotinib. Myeloproliferative neoplasm [2A20] [32]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Dasatinib. Myeloproliferative neoplasm [2A20] [65]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Daunorubicin and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [66]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Promethazine. Nausea/vomiting [MD90] [32]
Rolapitant DM8XP26 Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Rolapitant. Nausea/vomiting [MD90] [67]
Granisetron DMIUW25 Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Granisetron. Nausea/vomiting [MD90] [32]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Daunorubicin and Dolasetron. Nausea/vomiting [MD90] [32]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Ondansetron. Nausea/vomiting [MD90] [32]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Entrectinib. Non-small cell lung cancer [2C25] [36]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Daunorubicin and Levomethadyl Acetate. Opioid use disorder [6C43] [33]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Lofexidine. Opioid use disorder [6C43] [32]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Rucaparib. Ovarian cancer [2C73] [32]
Buprenorphine DMPRI8G Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Buprenorphine. Pain [MG30-MG3Z] [32]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Triclabendazole. Parasitic worm infestation [1F90] [32]
Istradefylline DM20VSK Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Istradefylline. Parkinsonism [8A00] [35]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Pimavanserin. Parkinsonism [8A00] [68]
Apomorphine DMX38HQ Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Apomorphine. Parkinsonism [8A00] [32]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Famotidine. Peptic ulcer [DA61] [36]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Daunorubicin and Macimorelin. Pituitary gland disorder [5A60-5A61] [69]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Daunorubicin and Lefamulin. Pneumonia [CA40] [70]
Ritodrine DM4V6RL Moderate Increased risk of ventricular arrhythmias by the combination of Daunorubicin and Ritodrine. Preterm labour/delivery [JB00] [39]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Degarelix. Prostate cancer [2C82] [33]
ABIRATERONE DM8V75C Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by ABIRATERONE. Prostate cancer [2C82] [35]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Enzalutamide. Prostate cancer [2C82] [33]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Relugolix. Prostate cancer [2C82] [33]
Darolutamide DMV7YFT Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Darolutamide. Prostate cancer [2C82] [71]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Bicalutamide. Prostate cancer [2C82] [33]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Daunorubicin and Gatifloxacin. Respiratory infection [CA07-CA4Z] [72]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Daunorubicin and Canakinumab. Rheumatoid arthritis [FA20] [73]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Daunorubicin and Rilonacept. Rheumatoid arthritis [FA20] [73]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Daunorubicin and Golimumab. Rheumatoid arthritis [FA20] [74]
Leflunomide DMR8ONJ Major Additive immunosuppressive effects by the combination of Daunorubicin and Leflunomide. Rheumatoid arthritis [FA20] [51]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Quetiapine. Schizophrenia [6A20] [32]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Daunorubicin and Mesoridazine. Schizophrenia [6A20] [32]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Aripiprazole. Schizophrenia [6A20] [36]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Daunorubicin and Iloperidone. Schizophrenia [6A20] [32]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Paliperidone. Schizophrenia [6A20] [32]
Perphenazine DMA4MRX Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Perphenazine. Schizophrenia [6A20] [32]
Trifluoperazine DMKBYWI Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Trifluoperazine. Schizophrenia [6A20] [32]
Risperidone DMN6DXL Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Risperidone. Schizophrenia [6A20] [32]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Daunorubicin and Amisulpride. Schizophrenia [6A20] [75]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Asenapine. Schizophrenia [6A20] [32]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Daunorubicin and Pimozide. Schizophrenia [6A20] [33]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Daunorubicin when combined with Anthrax vaccine. Sepsis [1G40-1G41] [76]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Vardenafil. Sexual dysfunction [HA00-HA01] [32]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Daunorubicin and LEE011. Solid tumour/cancer [2A00-2F9Z] [32]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Daunorubicin and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [32]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [33]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [32]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Pitolisant. Somnolence [MG42] [32]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [32]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Daunorubicin caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [77]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Lenvatinib. Thyroid cancer [2D10] [32]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Daunorubicin and Cabozantinib. Thyroid cancer [2D10] [33]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Daunorubicin and Papaverine. Tonus and reflex abnormality [MB47] [78]
Tizanidine DMR2IQ4 Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Tizanidine. Tonus and reflex abnormality [MB47] [32]
Azathioprine DMMZSXQ Moderate Additive myelosuppressive effects by the combination of Daunorubicin and Azathioprine. Transplant rejection [NE84] [36]
Tacrolimus DMZ7XNQ Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Tacrolimus. Transplant rejection [NE84] [35]
Cinoxacin DM4EWNS Minor Decreased absorption of Daunorubicin due to intestinal mucosa variation caused by Cinoxacin. Urinary tract infection [GC08] [41]
Nalidixic acid DMRM0JV Minor Decreased absorption of Daunorubicin due to intestinal mucosa variation caused by Nalidixic acid. Urinary tract infection [GC08] [41]
Elagolix DMB2C0E Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Elagolix. Uterine fibroid [2E86] [35]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [79]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Daunorubicin and Procainamide. Ventricular tachyarrhythmia [BC71] [32]
Propafenone DMPIBJK Moderate Decreased clearance of Daunorubicin due to the transporter inhibition by Propafenone. Ventricular tachyarrhythmia [BC71] [35]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Daunorubicin and Flecainide. Ventricular tachyarrhythmia [BC71] [32]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Daunorubicin and Amiodarone. Ventricular tachyarrhythmia [BC71] [32]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of Daunorubicin and Ganciclovir. Virus infection [1A24-1D9Z] [36]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Daunorubicin and Valganciclovir. Virus infection [1A24-1D9Z] [36]
⏷ Show the Full List of 178 DDI Information of This Drug

References

1 Daunorubicin FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7063).
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer. 2004 Mar;40(4):536-42.
5 Mayer LD, Tardi P, Louie AC: CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties. Int J Nanomedicine. 2019 May 23;14:3819-3830. doi: 10.2147/IJN.S139450. eCollection 2019.
6 BDDCS applied to over 900 drugs
7 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8 FDA Approved Drug Products: Daunorubicin hydrochloride injection
9 Clinical pharmacokinetics of commonly used anticancer drugs. Clin Pharmacokinet. 1983 May-Jun;8(3):202-32. doi: 10.2165/00003088-198308030-00002.
10 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
11 Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res. 2008 May 1;68(9):3161-8. doi: 10.1158/0008-5472.CAN-07-6381.
12 Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. Br J Clin Pharmacol. 2016 Sep;82(3):683-95. doi: 10.1111/bcp.13008. Epub 2016 Jun 30.
13 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
14 31P NMR spectra of ethidium, quinacrine, and daunomycin complexes with poly(adenylic acid).poly(uridylic acid) RNA duplex and calf thymus DNA. Biochemistry. 1989 Apr 4;28(7):2804-12.
15 Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res. 2002 Nov 1;62(21):6172-7.
16 Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83.
17 Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001 Jul 6;285(1):111-7.
18 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
19 The effect of new lipophilic chelators on the activities of cytosolic reductases and P450 cytochromes involved in the metabolism of anthracycline antibiotics: studies in vitro. Physiol Res. 2004;53(6):683-91.
20 Lack of mechanism-based inactivation of rat hepatic microsomal cytochromes P450 by doxorubicin. Can J Physiol Pharmacol. 1999 Aug;77(8):589-97.
21 Flavonoids as inhibitors of human carbonyl reductase 1. Chem Biol Interact. 2008 Jul 30;174(2):98-108.
22 Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism. J Pharmacol Exp Ther. 2010 Mar;332(3):755-63.
23 Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment. Arch Toxicol. 2016 Nov;90(11):2763-2777.
24 Characterization of DNA reactive and non-DNA reactive anticancer drugs by gene expression profiling. Mutat Res. 2007 Jun 1;619(1-2):16-29. doi: 10.1016/j.mrfmmm.2006.12.007. Epub 2007 Feb 8.
25 Aldo-keto reductase 1C2 fails to metabolize doxorubicin and daunorubicin in vitro. Drug Metab Dispos. 2008 Jun;36(6):991-4. doi: 10.1124/dmd.108.020388. Epub 2008 Mar 5.
26 Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members. Biochem J. 1999 Oct 15;343 Pt 2(Pt 2):487-504.
27 Cancer biomarker AKR1B10 and carbonyl metabolism. Chem Biol Interact. 2009 Mar 16;178(1-3):134-7. doi: 10.1016/j.cbi.2008.10.044. Epub 2008 Nov 5.
28 Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile. Arch Toxicol. 2018 Sep;92(9):2845-2857.
29 Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci Rep. 2014 Sep 26;4:6437. doi: 10.1038/srep06437.
30 [Influence of arsenic trioxide and daunorubicin on the expression of annexin II and fibrinolytic activity in NB4 cells]. Zhonghua Xue Ye Xue Za Zhi. 2010 Dec;31(12):813-6.
31 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
32 Canadian Pharmacists Association.
33 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
34 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
35 Multum Information Services, Inc. Expert Review Panel.
36 Cerner Multum, Inc. "Australian Product Information.".
37 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
38 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
39 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
40 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
41 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
42 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
43 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
44 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
45 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
46 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
47 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
48 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
49 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
50 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
51 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
52 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
53 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
54 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
55 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
56 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
57 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
58 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
59 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
60 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
61 Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
62 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
63 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
64 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
65 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
66 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
67 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
68 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
69 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
70 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
71 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
72 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
73 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
74 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
75 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
76 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
77 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
78 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
79 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]